Q1 Earnings Estimate for TARS Issued By William Blair

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Analysts at William Blair issued their Q1 2026 earnings estimates for shares of Tarsus Pharmaceuticals in a note issued to investors on Tuesday, February 25th. William Blair analyst L. Hanbury-Brown anticipates that the company will post earnings per share of ($0.06) for the quarter. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals' Q2 2026 earnings at $0.32 EPS, Q3 2026 earnings at $0.56 EPS, Q4 2026 earnings at $0.80 EPS and FY2026 earnings at $1.62 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The business had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million.

Several other research analysts have also recently commented on TARS. The Goldman Sachs Group increased their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a research report on Friday, November 15th. HC Wainwright reissued a "buy" rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Guggenheim reissued a "buy" rating and issued a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Oppenheimer upped their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Finally, Barclays cut their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $61.33.

Remove Ads

Tarsus Pharmaceuticals Stock Down 4.0 %

Shares of Tarsus Pharmaceuticals stock traded down $1.76 during trading hours on Thursday, reaching $42.72. 736,091 shares of the company's stock were exchanged, compared to its average volume of 643,788. The stock has a market cap of $1.64 billion, a P/E ratio of -11.21 and a beta of 1.01. The company has a 50 day moving average of $50.97 and a two-hundred day moving average of $43.36. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a fifty-two week low of $20.08 and a fifty-two week high of $57.28.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Summit Investment Advisors Inc. raised its position in shares of Tarsus Pharmaceuticals by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock valued at $213,000 after purchasing an additional 244 shares during the period. Sherbrooke Park Advisers LLC raised its holdings in Tarsus Pharmaceuticals by 7.2% in the 4th quarter. Sherbrooke Park Advisers LLC now owns 6,571 shares of the company's stock valued at $364,000 after acquiring an additional 443 shares during the period. Crowley Wealth Management Inc. acquired a new stake in Tarsus Pharmaceuticals during the fourth quarter worth approximately $25,000. Bank of New York Mellon Corp lifted its position in Tarsus Pharmaceuticals by 0.5% during the fourth quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company's stock worth $5,644,000 after acquiring an additional 498 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in shares of Tarsus Pharmaceuticals by 1.2% during the fourth quarter. Swiss National Bank now owns 52,333 shares of the company's stock worth $2,898,000 after acquiring an additional 600 shares during the period. Institutional investors and hedge funds own 90.01% of the company's stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.